パーキンソン病におけるフォスレボドーパ/フォスカルビドーパ連続体注入:耐受性,注入速度の調整および併用薬の短期データ
Katarina Rukavina1, Georg Ebersbach1, Doreen Gruber1,2,3
1Movement Disorders Hospital Beelitz, Beelitz-Heilstätten, Germany.
Movement disorders clinical practice
|August 29, 2025
まとめ
フォスレボドーパ/フォスカルビドーパ (LDp/CDp) は,実際の使用において,パーキンソン病の運動変動を効果的に管理する. 皮膚反応のような管理可能な副作用があるため,より高い用量と組み合わせた治療がしばしば必要になります.
科学分野:
- 神経学
- 薬理学について
- 運動障害
背景:
- パーキンソン病 (PD) の臨床試験で,フォスレボドーパ/フォスカルビドーパ (LDp/CDp) が運動の変動を軽減する効果を示した.
- LDp/CDpの実際の耐受性および最適な投与量は,まだ十分に調査されていない.
研究 の 目的:
- LDp/CDpの臨床耐性を評価する.
- LDp/CDpの投与パターンと併用薬の調整を分析する.
主な方法:
- 単一センター,遡及的,横断的な研究が行われました.
- LDp/CDpで開始された53人のパーキンソン病 (PwP) のデータを分析した.
主要な成果:
- 平均LDp/ CDpの輸液量は,最適化後の推奨値 (0. 39 vs. 0. 32 ml/ h) を上回った.
- 併用される一般的な薬剤は,MAO- B阻害剤 (50%),COMT阻害剤 (44%),ドーパミンアゴニスト (12%) であった.
- 皮膚反応 (31%),精神病 (8%),吐き気 (2%),13人の患者が治療を中止した.
結論:
- LDp/CDpは,PDの運動変動に対する有効な非外科的治療法であるようです.
- 臨床実務では,より高い用量および組み合わせ療法が頻繁に採用されています.
- LDp/CDpは,現実の環境で許容できる.
関連する概念動画
Parkinson's Disease: Treatment
376
Neurodegenerative disorders, such as Parkinson's Disease (PD), involve the gradual and irreversible destruction of neurons in particular brain areas. These disorders exhibit standard features like proteinopathies, selective vulnerability of some neurons, and an interaction of intrinsic properties, genetics, and environmental influences in neural injury.
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
Parkinson's Disease is primarily a result of the loss of dopaminergic neurons in the substantia nigra pars compacta. The cornerstone of...
376
Parkinson's Disease: Overview
702
Neurodegenerative disorders are progressive diseases that cause irreversible damage and loss to neurons in specific brain areas. Examples of these disorders include Parkinson's disease, Alzheimer's disease, Multiple Sclerosis (MS), and Amyotrophic Lateral Sclerosis (ALS). These disorders share characteristics such as proteinopathies, selective neuronal vulnerability, and a complex interplay between genetic and environmental factors. The primary therapeutic goal for these conditions is...
702
Continuous Renal Replacement Therapy
129
Continuous Renal Replacement Therapy, also known as CRRT, is a procedural treatment for acute kidney injury (AKI) that gradually removes uremic toxins and fluids while maintaining acid-base balance and stabilizing electrolytes. It is particularly useful for hemodynamically unstable patients. Unlike intermittent hemodialysis, which is faster, CRRT provides a gentler approach over 24 hours, closely mimicking the function of natural kidneys. However, CRRT is not ideal for patients with...
129
Drug Delivery: Parenteral Route
827
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
827
Dosage Regimen: Fixed Dose
2.0K
Fixed-dose regimens are a common approach to administer drugs to achieve and maintain desired levels of the drug in the body. In this dosing strategy, a specific amount of medication is given at regular intervals, often multiple times a day, to ensure a consistent drug concentration in the bloodstream.
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
Fixed-dose regimens can be used for various routes of administration, including intravenous (IV) injections and oral medications. For IV administration, a predetermined amount of the drug is...
2.0K
Chemotherapy-Induced Nausea and Vomiting: Dopamine Receptor Antagonists
439
Dopamine receptor antagonists, also known as antipsychotic agents, are critical in managing chemotherapy-induced vomiting. These antiemetic agents block dopamine receptors in the chemoreceptor trigger zone (CTZ), inhibiting signal transmission to the vomiting center. Antipsychotic agents encompass phenothiazines (PTZ), butyrophenones, benzamides, and thienobenzodiazepines (Zyprexa), which are utilized for their antiemetic and sedative properties.
Phenothiazines, such as prochlorperazine...
Phenothiazines, such as prochlorperazine...
439


